

August 29, 2011

Dear Valued Customer,

We are pleased to send you this brief note to inform you that QIAGEN acquired Cellestis Ltd. (www.cellestis.com). The publicly listed Australian diagnostic company will also legally become part of QIAGEN as of today. With this acquisition QIAGEN adds the novel QuantiFERON® Sample & Assay Technology to its broad molecular diagnostic portfolio, with two products already launched involving this technology and the intention to further leverage it by developing assays that are highly synergistic with QIAGEN's product portfolio.

What are the implications of this acquisition for you as a customer?

- Most importantly, your contacts at QIAGEN (and Cellestis) will remain the same.
- No services for customers will be discontinued as a consequence of the deal. In fact, by combining the two companies, customers will actually be getting more services from contacts they already know and trust.
- Merging QIAGEN's leadership in sample and assay technologies with Cellestis' exceptional technological capabilities will allow us to offer new innovative solutions in the future.
- QIAGEN will be able to offer "pre-molecular" and molecular tests, i.e. to large reference laboratories, which perform HPV and QuantiFERON® tests, creating a stronger value proposition for these customers.

What are the additional products?

- QuantiFERON®-TB Gold (QFT) is a test for detection of latent tuberculosis (TB). Thanks to its numerous advantages over the 110-year-old Tuberculin Skin test (TST), QFT is rapidly emerging as standard of care for latent TB screening. The test has been approved in many countries, including the U.S. (pre-market approval, or PMA), Canada and Japan and has been CE marked for use in Europe. It is also included in several national guidelines.
- QuantiFERON®-CMV is a test for detection of cytomegalovirus (CMV), which is one of the most common and problematic infections in solid organ transplant recipients and immunosuppressed patients. This test has been CE marked in Europe and is currently available for research use only in the U.S.

We look forward to providing you with additional sample-to-result molecular diagnostic solutions. If you have any further questions, please feel free to contact your sales representative.

Sincerely,

A handwritten signature in grey ink, appearing to read "Helge Lubenow".

Dr. Helge Lubenow
Global Head of Molecular Diagnostic Business, QIAGEN